A retrospective study evaluating effectiveness of primary brain radiotherapy with TKI for driver gene mutation-positive advanced non-small cell lung cancer with asymptomatic brain metastases.

A retrospective study evaluating effectiveness of primary brain radiotherapy with TKI for driver gene mutation-positive advanced non-small cell lung cancer with asymptomatic brain metastases. - A retrospective study evaluating effectiveness of primary brain radiotherapy with TKI for driver gene mutation-positive advanced non-small cell lung cancer with asymptomatic brain metastases.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046961

Enrollment

300

Registered

2022-02-21

Start date

2022-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Pathologically diagnosed as non-small cell lung cancer. 2. Driver gene positive has been confirmed and treated with the corresponding TKI. 3. A head imaging examination is performed before the first use of TKI. 4. Have brain metastases on first use of TKI. 5. Informed consent.

Exclusion criteria

Exclusion criteria: 1. The physician has determined that it is inappropriate.

Design outcomes

Primary

Measure	Time frame
intracranial progression free survival	—

Secondary

Measure	Time frame
overall survival, best overall response of intracranial lesions, time to onset of central nervous system symptoms, TKI treatment period, progression free survival, best overall response, safety of head radiation therapy	—

Countries

Japan

Contacts

Public ContactTakae Okuno

Shimane University Hospital Medical Oncology and Respiratory Medicine

takae007@med.shimane-u.ac.jp0853202580

Outcome results